These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38372753)

  • 1. Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator.
    Zylla MM; Wolfes J; Schleberger R; Lawin D; Kieser M; Reinke F; Eckardt L; Rillig A; Stellbrink C; Thomas D; Frey N; Lugenbiel P
    Clin Res Cardiol; 2024 Jun; 113(6):933-941. PubMed ID: 38372753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.
    Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A;
    Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of antiarrhythmic or implantable cardioverter defibrillator treated patients with varying degrees of left ventricular dysfunction who survived malignant ventricular arrhythmias.
    Domanski MJ; Epstein A; Hallstrom A; Saksena S; Zipes DP
    J Cardiovasc Electrophysiol; 2002 Jun; 13(6):580-3. PubMed ID: 12108501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy.
    Hyman MC; Mustin D; Supple G; Schaller RD; Santangeli P; Arkles J; Lin D; Muser D; Dixit S; Nazarian S; Epstein AE; Callans DJ; Marchlinski FE; Frankel DS
    Heart Rhythm; 2018 Feb; 15(2):159-163. PubMed ID: 29405947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.
    Das MK; Zipes DP
    J Cardiovasc Pharmacol; 2010 May; 55(5):438-49. PubMed ID: 20509177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.
    Arenal Á; Ávila P; Jiménez-Candil J; Tercedor L; Calvo D; Arribas F; Fernández-Portales J; Merino JL; Hernández-Madrid A; Fernández-Avilés FJ; Berruezo A
    J Am Coll Cardiol; 2022 Apr; 79(15):1441-1453. PubMed ID: 35422240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators.
    Domanski MJ; Sakseena S; Epstein AE; Hallstrom AP; Brodsky MA; Kim S; Lancaster S; Schron E
    J Am Coll Cardiol; 1999 Oct; 34(4):1090-5. PubMed ID: 10520795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.
    J Am Coll Cardiol; 1999 Nov; 34(5):1552-9. PubMed ID: 10551706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
    Hilleman DE; Bauman AL
    Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
    Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
    Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators.
    Van Herendael H; Pinter A; Ahmad K; Korley V; Mangat I; Dorian P
    Europace; 2010 May; 12(5):618-25. PubMed ID: 20304841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A history of heart failure predicts arrhythmia treatment efficacy: data from the Antiarrythmics versus Implantable Defibrillators (AVID) study.
    Brodsky MA; McAnulty J; Zipes DP; Baessler C; Hallstrom AP;
    Am Heart J; 2006 Oct; 152(4):724-30. PubMed ID: 16996848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.